Skip to main content
Top

13-06-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

Expert commentary: The DUAL VIII trial

print
PRINT
insite
SEARCH

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).


More on this topic

News story | IDegLira delays need for treatment intensification over glargine
News story | Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes
News story | Real-world data confirm benefits of IDegLira​​​​​​​

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »